Biotechnology - Biotechnology, Hematology

Filter

Current filters:

BiotechnologyHematology

Popular Filters

Baxter opens its first state-of-the-art biologics facility in Asia

Baxter opens its first state-of-the-art biologics facility in Asia

08-08-2014

US drugmaker Baxter International has formally opened its S$370 million ($297 million) first advanced…

AdvateBaxter InternationalBiotechnologyEuropean Medicines AgencyHematologyHemophilia BProductionSingapore

EU approval for Octapharma's Nuwiq across all age groups in hemophilia A

EU approval for Octapharma's Nuwiq across all age groups in hemophilia A

07-08-2014

The European Commission has approved independent Swiss biotech firm Octapharma's Nuwiq (simoctocog alfa)…

BiotechnologyEuropeHematologyNuwiqOctapharmaRegulation

Baxter buys AesRx, gaining rights to investigational SCD drug

Baxter buys AesRx, gaining rights to investigational SCD drug

10-07-2014

US drugmaker Baxter International said yesterday that it has acquired AesRx, a private US biopharmaceutical…

Aes-103AesRxBaxter InternationalBiotechnologyHematologyMergers & AcquisitionsRare diseasesUSA

Bayer strikes deal with Dimension Therapeutics to develop hemophilia A gene therapy

23-06-2014

USA-based venture capital;-backed biotech Dimension Therapeutics has entered into a collaboration with…

BayerBiotechnologyDimension TheapeuticsHematologyLicensingResearch

Geron leaps as FDA lifts partial hold on imetelstat trial

Geron leaps as FDA lifts partial hold on imetelstat trial

13-06-2014

US biotech Geron Corp's shares jumped around 27% to $3.31 in early afternoon trading yesterday after…

BiotechnologyGeron CorpHematologyimetelstatOncologyRegulationUSA

arGEN-X partners on ARGX-110 for Waldenstrom’s macroglobulinemia

arGEN-X partners on ARGX-110 for Waldenstrom’s macroglobulinemia

10-06-2014

Dutch/Belgian preclinical stage biotech company arGEN-X, has entered into a partnership with The Leukemia…

arGEN-XARGX-110BiotechnologyHematologyOncologyResearch

Biogen Idec’s Eloctate gains FDA approval

Biogen Idec’s Eloctate gains FDA approval

09-06-2014

The US Food and Drug Administration on Friday approved US biotech firm Biogen Idec’s Eloctate, antihemophilic…

Biogen IdecBiotechnologyEloctateHematologyRegulationSwedish Orphan BiovitrumUSA

CSL opens Australian biotechnology manufacturing facility

09-05-2014

Leading Australian biotech firm CSL Limited has opened the CSL Behring Biotechnology manufacturing facility…

AustraliaBiotechnologyCSL BehringCSL LimitedHematologyProductionResearch

Biogen Idec exercises option for Amunix’ XTENylated Factor VIII

21-04-2014

US privately-held biotech firm Amunix Operating says that Biogen Idec has exercised its option to enter…

AmunixBiogen IdecBiotechnologyHematologyLicensing

Baxter to acquire Chatham Therapeutics for $70 million

03-04-2014

USA-based Baxter International says it has agreed to acquire Chatham Therapeutics, a private biotechnology…

Baxter InternationalBiotechnologyChatham TherapeuticsHematologyMergers & Acquisitions

US FDA clears Biogen Idec and SOBI’s Alprolix for hemophilia B

US FDA clears Biogen Idec and SOBI’s Alprolix for hemophilia B

31-03-2014

Marking a second regulatory hurdle for the breakthrough product, the US Food and Drug Administration…

AlprolixBenefixBiogen IdecBiotechnologyCSL LimitedHematologyNorth AmericaNovo NordiskPfizerRegulationSwedish Orphan BiovitrumUSA

Emmaus Life Sciences releases top Phase III results for sickle cell anemia treatment

Emmaus Life Sciences releases top Phase III results for sickle cell anemia treatment

20-03-2014

US biotech company Emmaus Life Sciences, which focuses on orphan diseases, has announced preliminary…

BiotechnologyHematologyResearchUSA

Idelalisib may represent promising treatment for stubborn blood cancers

11-03-2014

A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma…

BiotechnologyGilead SciencesHematologyidelalisibOncologyResearch

Genentech regains its dominance in image among oncologists

Genentech regains its dominance in image among oncologists

20-02-2014

Genentech, the biotechnology subsidiary of Swiss drug major Roche, has made notable gains as the top…

AmgenBiotechnologyCelgeneGenentechHematologyMarkets & MarketingNovartisOncologyResearch

Biogen Idec and Sangamo BioSciences collaborate on blood disorder therapeutics

Biogen Idec and Sangamo BioSciences collaborate on blood disorder therapeutics

10-01-2014

US biotech firm Biogen Idec and Sangamo Biosciences have signed an exclusive worldwide collaboration…

Biogen IdecBiotechnologyHematologyLicensingResearchSangamo BioSciences

Janssen in-licenses rights to novel cancer therapy from CSL

Janssen in-licenses rights to novel cancer therapy from CSL

05-12-2013

Australian blood products and vaccine maker CSL Ltd has entered into an agreement with Janssen Biotech,…

BiotechnologyCSL LimitedHematologyImmunologicalsJanssen BiotechJohnson & JohnsonLicensingOncology

US FDA delays Alprolix approval

US FDA delays Alprolix approval

02-12-2013

The US Food and Drug Administration (has extended the initial Prescription Drug User Fee Act date for…

AlprolixBiogen IdecBiotechnologyHematologyNorth AmericaRegulationSwedish Orphan BiovitrumUSA

Biogen and SOBI announce top line results for hemophilia A treatment Eloctate

Biogen and SOBI announce top line results for hemophilia A treatment Eloctate

14-11-2013

US biotech major Biogen Idec (Nasdaq: BIIB) and Swedish Orphan Biovitrum (STO: SOBI) have announced detailed…

Biogen IdecBiotechnologyEloctateHematologyNorth AmericaResearchSobiUSA

US FDA calls for further data on Biogen Idec’s Eloctate

US FDA calls for further data on Biogen Idec’s Eloctate

13-11-2013

Swedish Orphan Biovitrum has announced that its partner, US biotech major Biogen Idec, has received a…

Biogen IdecBiotechnologyEloctateHematologyNorth AmericaRegulationSwedish Orphan Biovitrum

Celgene 3rd-qtr beats expectations; raises earnings guidance

25-10-2013

US biotech company Celgene Corp reported third quarter 2013 total revenue of $1.67 billion compared to…

BiotechnologyCelgeneFinancialHematologyOncology

Company Spotlight

ImmunoGen

ImmunoGen

Back to top